On this page
Earlier report,
Govt to cap trade margins at 30% of MRP on non-scheduled anti-cancer drugs, cutting prices of 110 medicines
Our read
The 30% of MRP cap on non-scheduled anti-cancer drugs is likely to be notified largely as announced, with trade pushback winning at most a short transition window rather than a rollback.
For operators
Pharmacy chains and distributors should prepare for lower per-pack earnings on 110 anti-cancer drugs, including 35 patented ones, once the 30% of MRP trade margin cap takes effect later this month, so they should reprice stock and review oncology inventory now.
Watch
Publication of the official notification and the final list of 110 drugs, including its effective date
Ask next
The report
The government will cap trade margins at 30 per cent of MRP for all non-scheduled anti-cancer drugs, government sources said on 8 October 2026. The cap will lower prices of 110 drugs, including 35 patented medicines, and is expected to take effect later this month.
- Trade margin cap on non-scheduled anti-cancer drugs
- 30% of MRP
- Anti-cancer drugs with lower prices
- 110
- Patented medicines among them
- 35
What we verified
Checked against the other reports of this story.
- Trade margin cap proposed on anti-cancer drugs: 30% — Moneycontrol and NDTV Profit agree.
Why it matters to operators
A 30% of MRP trade margin cap on non-scheduled anti-cancer drugs, cutting prices of 110 medicines, puts oncology margins at risk for pharmacy retailers and distributors, though the sources give no revenue estimate and confidence is moderate at 78.
What to watch next
- Statements or legal challenges from chemist, distributor or pharma industry associations
- Revised MRP lists from manufacturers of the 35 patented medicines
- Reports of stock shortages or order delays for cancer drugs at retail and hospital pharmacies
- Any government statement on extending margin caps to other drug categories
Updates
Each later report on this story, newest first. Earlier entries are never edited; a correction is a new entry.
Centre proposes 30% trade margin cap on anti-cancer drugs; Supreme Court says it is not enough
- Expected MRP reduction: 20-70%
- Expected annual consumer savings: Rs 2500 crore
- Standard retail margin for scheduled drugs under DPCO 2013: 16%
- MRP versus price to sellers for some drugs: 400 times
- Next Supreme Court hearing: 27 October
On the record
Earlier Government of India reports on RetailIntel, newest first.